Back to Directory

Cheryl Blanchette

Email

ccokley@fhi360.org

Phone

(919) 544-7040 x11359

Institution

FHI 360

Address

FHI360
359 Blackwell Street
Suite 200
Durham, NC 27701

Request an Update

Affiliated Studies

IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Pharmacokinetics, and antiviral activity of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed HIV-Infected Children >2 to <12 years of age and weighing >10 kgs and <50 kgs

Research Area

Study Status

IMPAACT 2009 : Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for Primary HIV Prevention during Pregnancy and Postpartum in Adolescents and Young Women and their Infants

DAIDS Number

Research Area

Study Status

IMPAACT 2010: VESTED

DAIDS Number

Research Area

Study Status

Participants Off Study and Primary Analysis Completed

P1108: A Phase I/II, Open-Label, Single Arm Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Bedaquiline (BDQ) in Combination with Optimized Individualized Multidrug-Resistant Tuberculosis (MDR-TB) Therapy in HIV-Infected and HIV-Uninfected Infants, Children and Adolescents with MDR-TB Disease

DAIDS Number

Research Area

Study Status

IMPAACT 2017: MOCHA

DAIDS Number

Research Area

Study Status

Show All